Company
Immunocore LTD
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
2
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 110
Recent approvals
Originals and efficacy supplements, newest first.
- Kimmtrak approved NovelBreakthrough therapyPriority reviewOrphanJan 25, 2022
Drugs in development (2)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- BrenetafuspIMC-F106CPhase 32 trials
Immunocore Ltd · Select Advanced Solid Tumors, Advanced Melanoma
- Monoclonal antibodyPhase 22 trials
Immunocore Ltd · Cancer, HLA-A*02:01-positive, Refractory Cancer
Recruiting Phase 3 trials
Largest first.
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Pivotal-lookingRecruiting
Immunocore LtdIndustry
NCT06112314 · 680 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 16, 2027
Drug: Brenetafusp; Nivolumab and 1 more · For: Advanced Melanoma
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 211 sites in all
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Pivotal-lookingRecruiting
Immunocore LtdIndustry
NCT05549297 · 540 participants (planned) · Start Dec 19, 2022 · Primary completion Mar 2028
Drug: Tebentafusp; Tebentafusp with Pembrolizumab and 1 more · For: Advanced Melanoma
Sites: Phoenix, Arizona; Jacksonville, Florida; Orlando, Florida · 82 sites in all
Marketed drugs (1)
Newest FDA action first.
- Kimmtrak Tebentafusp-Tebn · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.